Headlines Expert Newsletters Covid-19 Specialties Trending Feeds Videos

The FDA has approved sacituzumab govitecan-hziy (Trodelvy) for the treatment of adult patients with unresectable locally advanced or metastatic hormone receptor–positive, HER2-negative breast cancer...

Mridula George, MD, discusses the methods used to evaluate cardiotoxicity associated with adjuvant trastuzumab emtansine plus concurrent radiation therapy, and explains implications on the...

For Kevin Kalinsky, MD, MS, director of breast medical oncology at the Winship Cancer Institute of Emory University in Atlanta, Georgia, his work on...

Stephanie A. Berg, DO, discussed the implications of these findings on the urothelial cancer treatment paradigm and how updated results may further influence the...

Neoadjuvant pembrolizumab was found to have high clinical activity and an acceptable safety profile in patients with localized microsatellite instability–high/deficient mismatch repair solid...

Atish D. Choudhury, MD, PhD, discussed the significance of these trials within the metastatic castration-resistant prostate cancer treatment landscape, highlighted investigative PARP inhibitor combinations,...

Merck is discontinuing the phase 3 KEYNOTE-991 trial evaluating pembrolizumab plus enzalutamide and androgen deprivation therapy vs placebo plus enzalutamide/ADT in patients with metastatic...

Timothy Burns, MD, PhD, discusses the evolution of EGFR-targeted non–small cell lung cancer treatments, the importance of delineating small cell lung cancer subtypes, and...

Mridula George, MD, discusses the methods used to evaluate cardiotoxicity associated with adjuvant trastuzumab emtansine plus concurrent radiation therapy, and explains implications on the...

Zolbetuximab demonstrated a survival benefit and a tolerable safety profile when combined with mFOLFOX6 vs mFOLFOX6 plus placebo in patients with CLDN18.2-positive, HER2-negative locally...

  • 1619455398100013057 Profile photo of Madelyn

    Zolbetuximab demonstrated a survival benefit when combined w/ mFOLFOX6 vs mFOLFOX6 + placebo in CLDN18.2-positive, HER2-negative locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma. @KoheiShitara #oncology https://t.co/bVbJF79yUs - view on twitter